Calcium Regulation and Bone Mineral Metabolism in Elderly Patients with Chronic Kidney Disease

Overview

Journal Nutrients

Date 2013 Jun 14

PMID 23760058

Citations 13

Authors

Vickram Tejwani

Qi Qian

Affiliations

Soon will be listed here.

Abstract

The elderly chronic kidney disease (CKD) population is growing. Both aging and CKD can disrupt calcium (Ca2+) homeostasis and cause alterations of multiple Ca2+-regulatory mechanisms, including parathyroid hormone, vitamin D, fibroblast growth factor-23/Klotho, calcium-sensing receptor and Ca2+-phosphate product. These alterations can be deleterious to bone mineral metabolism and soft tissue health, leading to metabolic bone disease and vascular calcification and aging, termed CKD-mineral and bone disorder (MBD). CKD-MBD is associated with morbid clinical outcomes, including fracture, cardiovascular events and all-cause mortality. In this paper, we comprehensively review Ca2+ regulation and bone mineral metabolism, with a special emphasis on elderly CKD patients. We also present the current treatment-guidelines and management options for CKD-MBD.

Citing Articles

Relationship between bone turnover markers and renal disease in elderly patients with type 2 diabetes: a cross-sectional study.

Wei S, Pan X, Wei J BMC Endocr Disord. 2024; 24(1):179.

PMID: 39237970 PMC: 11378410. DOI: 10.1186/s12902-024-01698-y.

Association of urinary calcium excretion with chronic kidney disease in patients with type 2 diabetes.

Wang Y, Chen Y, Yu Y, Pan X, Fu G Int Urol Nephrol. 2024; 56(8):2715-2723.

PMID: 38498272 DOI: 10.1007/s11255-024-03978-x.

Nutritional Status and Serum Levels of Micronutrients in an Elderly Group Who Participate in the Program for Complementary Food in Older People (PACAM) from the Metropolitan Region, Santiago de Chile.

Arazo-Rusindo M, Zuniga R, Cortes-Segovia P, Benavides-Valenzuela S, Perez-Bravo F, Castillo-Valenzuela O Nutrients. 2022; 14(1).

PMID: 35010878 PMC: 8746835. DOI: 10.3390/nu14010003.

Association between metabolic parameters and risks of anemia and electrolyte disturbances among stages 3-5 chronic kidney disease patients in Taiwan.

Kurniawan A, Yang Y, Hsu C, Paramastri R, Lee H, Ni P BMC Nephrol. 2021; 22(1):385.

PMID: 34789178 PMC: 8600925. DOI: 10.1186/s12882-021-02590-w.

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.

Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Yoshikawa K, Tsuchiya A Clin Exp Nephrol. 2020; 25(1):66-79.

PMID: 32816132 PMC: 7794109. DOI: 10.1007/s10157-020-01936-2.

References

Deb D, Sun T, Wong K, Zhang Z, Ning G, Zhang Y . Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010; 77(11):1000-9. DOI: 10.1038/ki.2010.22. View

Araujo Martini L, Wood R . Milk intake and the risk of type 2 diabetes mellitus, hypertension and prostate cancer. Arq Bras Endocrinol Metabol. 2009; 53(5):688-94. DOI: 10.1590/s0004-27302009000500021. View

Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T . Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010; 78(10):975-80. DOI: 10.1038/ki.2010.313. View

Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T . PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010; 299(4):F882-9. DOI: 10.1152/ajprenal.00360.2010. View

Vaidya A, Sun B, Larson C, Forman J, Williams J . Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study. J Clin Endocrinol Metab. 2012; 97(7):2456-65. PMC: 3387405. DOI: 10.1210/jc.2012-1156. View

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

Toke J, Czirjak G, Patocs A, Enyedi B, Gergics P, Csakvary V . Neonatal severe hyperparathyroidism associated with a novel de novo heterozygous R551K inactivating mutation and a heterozygous A986S polymorphism of the calcium-sensing receptor gene. Clin Endocrinol (Oxf). 2007; 67(3):385-92. DOI: 10.1111/j.1365-2265.2007.02896.x. View

Reid I, Schooler B, Hannan S, IBBERTSON H . The acute biochemical effects of four proprietary calcium preparations. Aust N Z J Med. 1986; 16(2):193-7. DOI: 10.1111/j.1445-5994.1986.tb01147.x. View

Moranne O, Froissart M, Rossert J, Gauci C, Boffa J, Haymann J . Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2008; 20(1):164-71. PMC: 2615728. DOI: 10.1681/ASN.2008020159. View

10.

Vennekens R, Hoenderop J, Prenen J, Stuiver M, Willems P, Droogmans G . Permeation and gating properties of the novel epithelial Ca(2+) channel. J Biol Chem. 2000; 275(6):3963-9. DOI: 10.1074/jbc.275.6.3963. View

11.

Pollak M, Brown E, Chou Y, Hebert S, Marx S, Steinmann B . Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell. 1993; 75(7):1297-303. DOI: 10.1016/0092-8674(93)90617-y. View

12.

Balion C, Griffith L, Strifler L, Henderson M, Patterson C, Heckman G . Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012; 79(13):1397-405. PMC: 3448747. DOI: 10.1212/WNL.0b013e31826c197f. View

13.

Ohnishi M, Razzaque M . Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010; 24(9):3562-71. PMC: 2923352. DOI: 10.1096/fj.09-152488. View

14.

Bosworth C, Levin G, Robinson-Cohen C, Hoofnagle A, Ruzinski J, Young B . The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int. 2012; 82(6):693-700. PMC: 3434313. DOI: 10.1038/ki.2012.193. View

15.

Theman T, Collins M, Dempster D, Zhou H, Reynolds J, Brahim J . PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res. 2008; 24(5):964-73. PMC: 2672210. DOI: 10.1359/jbmr.081233. View

16.

Heath 3rd H, Hodgson S, Kennedy M . Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980; 302(4):189-93. DOI: 10.1056/NEJM198001243020402. View

17.

Pilz S, Iodice S, Zittermann A, Grant W, Gandini S . Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011; 58(3):374-82. DOI: 10.1053/j.ajkd.2011.03.020. View

18.

Haussler M, Jurutka P, Mizwicki M, Norman A . Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)₂vitamin D₃: genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):543-59. DOI: 10.1016/j.beem.2011.05.010. View

19.

Hebert S, Brown E, Harris H . Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. J Exp Biol. 1997; 200(Pt 2):295-302. DOI: 10.1242/jeb.200.2.295. View

20.

Kanzawa M, Sugimoto T, Kanatani M, Chihara K . Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol. 2000; 142(6):661-4. DOI: 10.1530/eje.0.1420661. View